The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Targeting the ERBB family in cancer: couples therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Self-citationCobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gómez, H., Dinh, P., Fauria, K., Van Dooren, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,317
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3309 · Cited by 988
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
The MAPK pathway across different malignancies: A new perspective
Burotto, M., Chiou, V. L., Lee, J., & Kohn, E. C. (2014) · Cancer · doi:10.1002/cncr.28864 · Cited by 956
PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
Kooijmans, S. A. A., Fliervoet, L. A. L., van der Meel, R., Fens, M. H. A. M., Heijnen, H. F. G., van Bergen en Henegouwen, P. M. P., Vader, P., & Schiffelers, R. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.009 · Cited by 625
Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells
Ma, S., Henson, E. S., Chen, Y., & Gibson, S. B. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.208 · Cited by 622
Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 591
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
RAB31 marks and controls an ESCRT-independent exosome pathway
Wei, D., Zhan, W., Gao, Y., Huang, L., Gong, R., Wang, W., Zhang, R., Wu, Y., Gao, S., & Kang, T. (2021) · Cell Research · doi:10.1038/s41422-020-00409-1 · Cited by 492
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Kooijmans, S. A. A., Aleza, C. G., Roffler, S. R., van Solinge, W. W., Vader, P., & Schiffelers, R. M. (2016) · Journal of Extracellular Vesicles · doi:10.3402/jev.v5.31053 · Cited by 426
Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements
Malki, A., ElRuz, R. A., Gupta, I., Allouch, A., Vranic, S., & Al Moustafa, A.-E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010130 · Cited by 398
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Tian, F., Zhang, S., Liu, C., Han, Z., Liu, Y., Deng, J., Li, Y., Wu, X., Cai, L., Qin, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22913-7 · Cited by 291
Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010445 · Cited by 117
The ERBB network facilitates KRAS-driven lung tumorigenesis
Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2565 · Cited by 111
Progress toward Overcoming Hypoxia-Induced Resistance to Solid Tumor Therapy
Reginato, M., & Karakashev, S. (2015) · Cancer Management and Research · doi:10.2147/cmar.s58285 · Cited by 95
Spaans, J. N., & Goss, G. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00190 · Cited by 57
Zhang, J., Cao, J., Li, J., Zhang, Y., Chen, Z., Peng, W., Sun, S., Zhao, N., Wang, J., Zhong, D., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-7-22 · Cited by 40
Metadata
- Authors
- Tebbutt, N., Pedersen, M. W., & Johns, T. G.
- Venue
- Nature Reviews Cancer
- Published
- 2013-08-16
- Volume
- 13
- Issue
- 9
- Pages
- 663-673
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2005202092
- Cited by
- 466
- References
- 83
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.